Therapeutic effect and mechanism of urinary kallidinogenase combined with edaravone on acute cerebral infarction

Objective To observe the clinical efficacy of urinary kallidinogenase combined with edaravone in the treatment of the acute cerebral infarction(ACI) and its mechanism of neural protection. Methods Total 92 cases of ACI were randomly divided into control group and observation group. The observation group was given edaravone combined with urinary kallidinogenase,while the control group was given edaravone,the course was 14 days. The blood rheology index,serum TNF-α,IL-8 and MMP-9 and VEGF,ESS and BI score and the clinical efficacy were compared between the two groups. Results After the treatment,the indexes of the two groups were significantly decreased(P < 0. 01). Compared with the control group,the observation group decreased more significantly(P < 0. 01). After the treatment,the levels of serum TNF-α,IL-8 and MMP-9 in both groups decreased significantly,VEGF levels increased significantly(P < 0. 01),and these indexes in the observation group decreased more significantly and VEGF increased more significantly(P < 0. 01).After the treatment,the ESS and BI scores of the two groups were significantly higher than those before treatment(P <0. 01),and the improvement of the observation group was significantly better than the control group(P < 0. 01). The total effective rate of the observation group was 89. 1%,which was significantly higher than that of the control group(P <0. 01). Conclusion Urinary kallidinogenase combined with edaravone can be better in the treatment of ACI as compared with single edaravone by decreasing the serum levels of inflammatory cytokines,inhibiting the inflammatory injury,improving the blood supply in brain tissues,and promoting the recovery of neurological function.